KNSA
Kiniksa Pharmaceuticals Ltd
78.80$
+1.0%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 45.2% | 31.8% | 20.6% | 42.1% | 36.3% | 12.6% | 23.0% | 34.0% | 31.8% | 40.9% | 32.1% | 39.5% | 39.1% | 44.0% | 54.0% | 44.7% | 45.3% | 46.2% | 45.1% | 45.0% | 45.8% | 45.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 54.8% | 68.2% | 79.4% | 57.9% | 63.7% | 87.4% | 77.0% | 66.0% | 68.2% | 59.1% | 67.9% | 60.5% | 60.9% | 56.0% | 46.0% | 55.3% | 54.7% | 53.8% | 54.9% | 55.0% | 54.2% | 54.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 305.4% | 156.0% | 146.3% | 63.6% | 49.9% | 16.5% | 23.3% | 30.8% | 32.8% | 25.1% | 23.8% | 32.8% | 22.0% | 23.2% | 28.7% | 14.0% | 12.0% | 13.3% | 17.1% | 12.8% | 16.8% | 15.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 283.6% | 171.6% | 121.3% | 69.0% | 88.4% | 24.9% | 44.0% | 60.1% | 40.8% | 51.4% | 44.1% | 48.4% | 39.0% | 41.3% | 33.1% | 31.6% | 29.9% | 27.2% | 28.1% | 28.5% | 26.2% | 27.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 581.2% | 321.8% | 272.1% | 130.3% | 135.5% | 40.6% | 67.2% | 89.1% | 72.6% | 75.4% | 67.8% | 81.2% | 61.0% | 64.6% | 61.7% | 45.6% | 41.8% | 40.5% | 45.2% | 41.4% | 43.0% | 42.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -526.4% | -253.6% | -192.8% | -72.4% | -71.8% | 46.8% | 9.8% | -23.2% | -4.4% | -16.3% | 0.1% | -20.7% | -0.1% | -8.6% | -15.7% | 9.6% | 12.9% | 13.3% | 9.8% | 13.7% | 11.2% | 11.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.1% | 0.0% | 0.4% | 0.1% | 0.4% | 0.3% | 1.3% | 3.8% | – | – | 2.2% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -526.3% | -253.5% | -192.3% | -72.3% | -71.4% | 47.1% | 11.1% | -19.4% | -1.7% | -12.7% | 2.9% | -17.9% | 2.1% | -6.4% | -13.9% | 11.3% | 14.6% | 15.0% | 11.5% | 15.3% | 12.8% | 13.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 13.2% | -1.0% | 1.5% | 6.0% | 2.7% | -178.9% | 3.8% | 6.0% | -22.7% | 8.0% | -27.3% | 4.3% | 5.7% | 4.9% | -6.6% | 5.1% | 3.2% | 4.8% | 4.5% | 4.7% | 2.3% | 4.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -539.5% | -252.5% | -193.8% | -78.3% | -74.1% | 226.0% | 7.2% | -25.4% | 20.9% | -20.7% | 30.3% | -22.2% | -3.6% | -11.3% | -7.3% | 6.2% | 11.4% | 10.2% | 7.0% | 10.5% | 10.4% | 9.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -513.1% | -244.6% | -188.8% | -68.9% | -67.4% | 48.1% | 12.8% | -17.0% | -0.2% | -11.2% | 3.2% | -17.3% | 2.5% | -6.1% | -13.5% | 11.5% | 14.8% | 15.2% | 11.7% | 15.5% | 11.4% | 13.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.